Truist cuts Ideaya Biosciences stock price target on revised estimates

Truist cut its Ideaya Biosciences price target to $57 from $59 while maintaining a Buy rating, citing updated darovasertib estimates and a higher probability of success for DLL3. Ideaya discontinued its phase III neoadjuvant study, a decision Truist said could save $100 million to $125 million for higher-priority programs; the company reported a current ratio of 10.45 and more cash than debt. Ideaya expects initial company-sponsored IDE849 data by year-end 2026 or early 2027 and a potential darovasertib NDA submission in 2027.

Analysis

IDYA’s value is increasingly a portfolio of clinical and regulatory options, not a near-term earnings story. The capital saved by dropping the neoadjuvant study lowers execution and funding pressure, but an NCCN listing is not a substitute for randomized evidence or an FDA label; commercial uptake may therefore lag the bull case. The key diligence gap is the exact evidence and regulatory path supporting darovasertib’s potential label, plus the company’s commercial rights and launch economics. Verify these before underwriting 2027 revenue.

Near term, the target reduction is unlikely to change the thesis: analyst ratings and targets are not independent validation of probability of success. The November 16 R&D day is more likely to move sentiment through strategy and trial design than through new efficacy data. The more consequential catalyst window is year-end 2026/early 2027 for IDE849 data, followed by the darovasertib filing path. Positive updates could expand the multiple; any delay, weaker-than-expected data, or narrowing of the potential label could rapidly compress it. The cash position buys time, but does not remove clinical or dilution risk if programs disappoint or spend accelerates.

Contrarian point: the market may be treating a possible 2027 transition as if it were already de-risked. Conversely, the abandoned trial’s avoided spend may be underappreciated if it materially extends runway while focusing resources on higher-priority assets. Neither effect is quantifiable from the supplied information; monitor burn, trial timelines, and rights economics rather than treating the analyst target as fair value.

Key Decisions for Investors

• Do not trade solely on the price-target change. Keep IDYA on a catalyst watchlist until the November 16 presentation clarifies the MTAP/CDKN2A-plus-RAS strategy, trial milestones, and expected spend.
• For investors seeking exposure, favor a small, staged position over a full-size pre-data bet; consider pairing IDYA exposure with a short XBI position to reduce broad biotech-factor risk. Size for a substantial loss if a key study fails or the regulatory path slips.
• Treat the IDE849 update expected around year-end 2026/early 2027 as the higher-impact catalyst. Before adding, verify the data cut, partner Hengrui’s role and economics, and whether results support a clear next trial step.
• Falsify the bullish thesis if darovasertib’s filing or label path materially narrows or slips, IDE849 data fail to support progression, or reported cash burn shortens runway faster than expected; reassess on company guidance and trial updates rather than analyst ratings.